Viridian Therapeutics, Inc.\DE (VRDN) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 9 years, with Q3 2025 value amounting to $0.04.
- Viridian Therapeutics, Inc.\DE's Debt to Equity rose 4317.91% to $0.04 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.04, marking a year-over-year increase of 4317.91%. This contributed to the annual value of $0.03 for FY2024, which is 3295.96% down from last year.
- Viridian Therapeutics, Inc.\DE's Debt to Equity amounted to $0.04 in Q3 2025, which was up 4317.91% from $0.04 recorded in Q2 2025.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's Debt to Equity peaked at $0.05 during Q4 2023, and registered a low of $0.03 during Q3 2024.
- Its 3-year average for Debt to Equity is $0.04, with a median of $0.04 in 2024.
- In the last 5 years, Viridian Therapeutics, Inc.\DE's Debt to Equity crashed by 3295.96% in 2024 and then soared by 4317.91% in 2025.
- Viridian Therapeutics, Inc.\DE's Debt to Equity (Quarter) stood at $0.05 in 2023, then crashed by 32.96% to $0.03 in 2024, then surged by 35.53% to $0.04 in 2025.
- Its last three reported values are $0.04 in Q3 2025, $0.04 for Q2 2025, and $0.03 during Q1 2025.